Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 7

This study has been completed.

First Received on September 20, 1999. Last Updated on June 23, 2005 History of Changes

Sponsor:	National Institute on Drug Abuse (NIDA)
Collaborator:	University of Pennsylvania
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000358

Purpose

The purpose of this study is to determine the safety of lofexidine in the treatment of opiate withdrawal. Preliminary data will also be obtained to assess the ability of lofexidine to alleviate opiate withdrawal signs and symptoms.

Condition	Intervention	Phase
Opioid-Related Disorders Substance-Related Disorders	Drug: Lofexidine	Phase I

Study Type:	Interventional
Study Design:	Primary Purpose: Treatment
Official Title:	Safety Evaluation of Lofexidine for Treatment of Opioid Withdrawal

Resource links provided by NLM:

MedlinePlus related topics: Drug Abuse

Drug Information available for: Lofexidine hydrochloride Lofexidine

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Estimated Enrollment:

Eligibility

Ages Eligible for Study:	21 Years to 59 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000358

Locations

United States, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104 6178

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

University of Pennsylvania

Investigators

Principal Investigator:

Charles O'Brien, M.D., Ph.D.

PDVAMC Treatment Research Center

More Information

No publications provided

ClinicalTrials.gov Identifier:	NCT00000358 History of Changes
Other Study ID Numbers:	NIDA-3-0012-7, Y01-3-0012-7
Study First Received:	September 20, 1999
Last Updated:	June 23, 2005
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:

Opioid-Related Disorders
Substance Withdrawal Syndrome
Substance-Related Disorders
Mental Disorders
Lofexidine
Analgesics, Opioid
Antihypertensive Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions
Narcotic Antagonists
Physiological Effects of Drugs

Sensory System Agents
Peripheral Nervous System Agents
Central Nervous System Agents
Adrenergic alpha-2 Receptor Agonists
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Analgesics
Central Nervous System Depressants

ClinicalTrials.gov processed this record on February 12, 2012